Author

Rodrigo Ito

Observed name: Ito, Rodrigo

Institution: Eli Lilly (United States)

Observed institution: Eli Lilly (United States)

OpenAlex ID: A5010701937

BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma

2022 · Toby A Eyre, Nirav N Shah, et al. · Future Oncology · 26

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Journal of Clinical Oncology · 16

MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)

2022 · Rodrigo Ito, Toby A. Eyre, et al. · Clinical Lymphoma Myeloma & Leukemia · 5

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

2025 · Wojciech Jurczak, Michal Kwiatek, et al. · Blood · 4

Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

2026 · Matthew S Davids, Toby A Eyre, et al. · The Lancet · 1

BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.

2023 · Michael Wang, Toby A. Eyre, et al. · Journal of Clinical Oncology · 1

CO190 Optimal Categorization of High Side-effect Bother Based on Functional Assessment of Cancer Therapy GP5 (FACT-GP5) Item Among Patients with MCL enrolled to BRUIN-MCL-321

2025 · Angely Loubert, Kristin Creel, et al. · Value in Health

Poster: MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)

2022 · Rodrigo Ito, Toby A. Eyre, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 9

Citation count: 53

H-index: 4

I10-index: 2